Changes in liver steatosis and liver stiffness following Empagliflozin treatment in patients with MASLD and type 2 diabetes: A single‐arm pre–post study
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) is common in subjects with type 2 diabetes mellitus (T2DM), being linked to a higher risk for the development of liver‐related and cardiovascular diseases. Sodium‐glucose cotransporter 2 (SGLT2) inhibitors such as empagliflozin have de...